Together, we would prefer to suggest a new indication of PTH for patients suffering from both osteoporosis and NAFLD, and a targeted PTH delivery system for liver-specific delivery awaits further investigation. This evidence concerns the gene PTH and metabolic dysfunction-associated steatotic liver disease.